Background and challenges

With increased life expectancy in modern society, the number of individuals who will potentially become demented is growing proportionally. Current estimates count world-wide over 48 million people suffering from dementia bringing the social cost of care to 1% of world’s gross domestic product – GDP. These numbers led the World Health Organisation to classify neurocognitive disorders as a global public health priority. Nowadays neuroimaging tools are essential in the diagnosis and treatment of individuals suffering from brain injuries and disorders. Compared to visual assessment, automated diagnostic methods based on brain imaging are more reproducible and have demonstrated a high accuracy in separating AD from healthy aging, but also the clinically more challenging separations between different types of neurocognitive disorders. Similarly, although ApoE genotypes carrying higher risk for AD are easily obtainable, this information is rarely integrated in machine learning-based diagnostics for AD. Although encouraging, implementations into clinical routine have been challenging.

The goal is to make data on populations of patients broadly available for research use by providing software-as-service to clinicians, neuroscientists, epidemiologists and pharma both for diagnosis and research in clinics and for collaborative neuroscience research using clinical data.

Video explains the use case scenario and benefits coming from MORPHEMIC: